ANIK Anika Therapeutics, Inc.

CIK 0000898437 41 ready 8-Ks latest July 29, 2026, 7:20 AM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (2)

Ready 8-Ks 41

Latest filing July 29, 2026, 7:20 AM ET

Top materiality 0.80

Event mix earnings ×21 · other_material ×6 · leadership ×6

Sentiment 11 pos · 5 neg · 25 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for ANIK

Highest-materiality recent filing

Anika Q2 revenue $32.6M (+16% YoY); raises FY 2026 guidance, adj. EBITDA margin 13-17%

July 29, 2026, 7:20 AM ET earnings materiality 0.80 positive item 2.02 item 9.01

Q2 revenue $32.6M, up 16% YoY; Commercial Channel record $13.9M (+17%); OEM $18.7M (+14%).
Gross margin 65%; net income $3.3M ($0.24 diluted EPS); adjusted EBITDA $7.1M (22% margin).

Read filing →

July 29, 2026, 7:20 AM ET earnings materiality 0.80 positive item 2.02 item 9.01

Anika Q2 revenue $32.6M (+16% YoY); raises FY 2026 guidance, adj. EBITDA margin 13-17%

Q2 revenue $32.6M, up 16% YoY; Commercial Channel record $13.9M (+17%); OEM $18.7M (+14%).
July 14, 2026, 5:00 PM ET debt materiality 0.45 neutral item 1.01 item 2.03 item 9.01

Anika Therapeutics enters Fifth Amendment to credit agreement, $50M revolver due 2031

$50M senior revolving credit facility with Bank of America, maturity July 10, 2031.
June 23, 2026, 4:05 PM ET other material materiality 0.20 neutral item 5.02 item 5.07 item 9.01

Anika shareholders approve share reserve increases for equity plans at annual meeting

Stockholders approved amendment to 2017 Omnibus Incentive Plan, increasing reserved shares from 5,760,000 to 6,110,000 (350,000 share increase).
April 29, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 5.02 item 9.01 ◈ Earnings Releases ×2◈ executive_change ×2

Anika Q1 revenue up 13% to $29.6M; adjusted EBITDA improves to $4.3M; directors resign

Total revenue $29.6M (+13% YoY); Commercial Channel +12%, OEM +14%.
February 26, 2026, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 5.02 item 9.01

Anika Q4 rev flat, FY rev -6%; guides 2026 rev $114-122.5M; GC Colleran to depart May 1

Q4 revenue $30.6M flat YoY; GAAP EPS $0.13, adjusted EPS $0.31; gross margin 63%.
January 8, 2026, 6:59 PM ET leadership materiality 0.70 neutral item 2.02 item 5.02 item 9.01

Anika Therapeutics appoints Steve Griffin CEO effective Feb 1, 2026; Cheryl Blanchard becomes Executive Chair

Steve Griffin, current CFO & COO, promoted to President and CEO effective Feb 1, 2026.
November 5, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 8.01 item 9.01

Anika Q3 revenue down 6% to $27.8M; files final Hyalofast PMA with mixed Phase III data

Q3 continuing ops rev $27.8M (-6% YoY); loss per share ($0.22); adj EPS $0.04; adj EBITDA $0.9M.
July 30, 2025, 7:59 PM ET regulatory materiality 0.65 negative item 7.01 item 9.01

Anika's Hyalofast Phase III misses co-primary endpoints; plans PMA filing by end of 2025

Hyalofast missed pre-specified co-primary endpoints (percent change in KOOS Pain and IKDC function vs microfracture) on statistical significance.
July 30, 2025, 7:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01

Anika Therapeutics Q2 2025 revenue down 8%; Hyalofast trial misses co-primary endpoints

Q2 2025 revenue $28.2M, down 8% YoY; Commercial Channel flat, OEM Channel down 13%
June 24, 2025, 7:59 PM ET other material materiality 0.40 neutral item 5.02 item 5.07 item 9.01

Anika Therapeutics stockholders approve 475,000-share increase in incentive plan

Share reserve under 2017 Omnibus Incentive Plan raised from 5,285,000 to 5,760,000.
May 9, 2025, 7:59 PM ET earnings materiality 0.65 negative item 2.02 item 9.01

Anika Q1 revenue down 10% to $26.2M; lowers FY2025 Adj. EBITDA guidance to -3% to 3%

Revenue $26.2M, down 10% YoY; OEM channel down 23% to $14.9M, Commercial channel up 18% to $11.3M.
April 10, 2025, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 ◈ executive_change

Anika Therapeutics announces departure of COO Anne Nunes, eliminates position

Anne Nunes departs as Chief Operations Officer effective April 25, 2025.
March 12, 2025, 7:59 PM ET earnings materiality 0.72 neutral item 2.02 item 9.01

Anika Therapeutics reports Q4 2024 revenue $30.6M, full year $119.9M; guides 2025 adj EBITDA margin 8-10%

Q4 revenue from continuing ops $30.6M (+1% YoY); full-year revenue $119.9M (-1% YoY).
March 11, 2025, 7:59 PM ET M&A materiality 0.55 positive item 2.01 item 7.01 item 9.01 ◈ M&A Transactions

Anika completes sale of Parcus Medical for $4.5M cash, sharpens focus on OA pain management

Sale closed March 7, 2025 to Medacta Group SA (Medacta Americas Manufacturing).
October 31, 2024, 7:59 PM ET M&A materiality 0.70 positive item 2.01 item 7.01 item 9.01 ◈ M&A Transactions

Anika Therapeutics completes sale of Arthrosurface for $10M; plans to divest Parcus Medical

Sold Arthrosurface to Phoenix Brio for $7M note plus up to $3M contingent consideration based on sales performance.
October 31, 2024, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01

Anika Q3 rev $38.8M (-7% YoY), net loss $29.9M; restructures, sells Arthrosurface, plans Parcus divestiture

Revenue $38.8M (-7% YoY), net loss $29.9M ($2.03/sh); adj net loss $3.8M ($0.25/sh).
August 8, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Anika Q2 revenue $41.9M (-5% YoY); net loss $0.1M; launches Integrity Implant System

Revenue $41.9M, down 5% YoY; OA Pain Mgmt $26.7M (-9%), Joint Preservation $13.5M (+7%).
July 11, 2024, 7:59 PM ET other materiality 0.10 neutral item 5.07

Anika Therapeutics stockholders elect directors and ratify auditor at 2024 annual meeting

Elected Sheryl L. Conley, William R. Jellison, Stephen O. Richard as Class I directors (2027 term).
May 28, 2024, 7:59 PM ET other material materiality 0.80 positive item 1.01 item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Anika Therapeutics adds two directors, announces $40M buyback under Caligan deal

Appointed Joseph Capper (MIMEDX CEO) and William Jellison (former Stryker CFO) to Board; board expands to 10 then reduces to 9 after 2024 annual meeting.
May 8, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

Anika Therapeutics Q1 revenue up 7% to $40.5M; narrows net loss; reaffirms FY2024 guidance

Q1 revenue $40.5M (+7% YoY); net loss narrowed to $4.5M from $10.4M; adjusted net income $1.2M ($0.09/dil share).
May 8, 2024, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 9.01 ◈ executive_change ×2

Anika Therapeutics appoints Stephen Griffin as CFO replacing Michael Levitz effective June 3, 2024

Stephen Griffin appointed EVP, CFO and Treasurer of Anika Therapeutics, effective June 3, 2024.
March 13, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases ×2

Anika Q4 revenue $43.0M (+8%), net loss incl. $62.2M impairment; guides FY2024 adj. EBITDA $25-30M

Q4 revenue $43.0M (+8% YoY); net loss ($63.0M) or ($4.30)/share due to $62.2M non-cash impairment on Arthrosurface/Parcus intangibles.
February 26, 2024, 6:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01 ◈ executive_change ×2

Director Jeffery S. Thompson to retire; John B. Henneman appointed Board Chair

Jeffery S. Thompson will retire from Anika's Board at the 2024 Annual Meeting after 13 years.
November 2, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Anika Q3 revenue $41.5M (+3% YoY); raises FY2023 guidance to $164-166M

Revenue $41.5M (+3% YoY); Joint Preservation & Restoration up 14% to $13.5M, OA Pain Mgmt up 2% to $24.9M.
September 21, 2023, 7:59 PM ET other material materiality 0.15 neutral item 7.01 item 9.01

Anika Therapeutics files investor presentation with pipeline updates; no financial details provided

Presentation for Sidoti Small Cap Conference dated September 21, 2023, furnished as Exhibit 99.1.
August 8, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Anika Q2 revenue rises 12% to $44.3M; raises FY2023 guidance floor to $159.5M

Q2 revenue $44.3M (+12% YoY); net loss ($0.19)/share; adjusted EPS $0.06 vs ($0.12) prior year.
June 21, 2023, 7:59 PM ET leadership materiality 0.35 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×5◈ executive_change

Anika appoints Anne Nunes as SVP, COO; shareholders approve 435K-share plan increase

Anne Nunes appointed SVP, Chief Operations Officer effective June 19, 2023; base salary $440,000, target bonus 45%.
May 9, 2023, 7:59 PM ET earnings materiality 0.65 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

Anika Q1 revenue up 3% to $37.9M but net loss widens to $10.4M

OA Pain Mgmt rev $22.6M (+8% YoY); Joint Preservation & Restoration rev $13.5M (+11% YoY).
April 28, 2023, 7:59 PM ET litigation materiality 0.45 neutral item 8.01 item 9.01

Anika Therapeutics pays $3.25M to settle Parcus Medical earnout arbitration

Paid $3.25M one-time settlement to Philip Mundy, Parcus Medical unitholder rep, to resolve earnout arbitration.
April 13, 2023, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 5.02 item 7.01 item 9.01 ◈ executive_change◈ Material Agreements

Anika enters cooperation with Caligan, appoints director, authorizes $20M buyback

Appointed Gary Fischetti as Class III director; Board expands to eight members.
March 6, 2023, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases ×3

Anika Q4 revenue up 11% to $39.6M; net loss $4.9M; FY2023 guidance $158-163M

Q4 revenue $39.6M (+11% YoY); OA Pain Mgmt $23.7M (+20%), Joint Preservation $14.3M (+8%).
November 8, 2022, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Anika Q3 revenue $40.3M (+2% YoY); net loss ($4.2M); Cingal Phase III hits endpoint

Revenue $40.3M (+2% YoY); OA Pain Mgmt $25.7M (-2%), Joint Preservation $11.8M (+6%), Non-Ortho $2.8M (+27%).
November 1, 2022, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

Anika's Cingal succeeds in Phase III 19-01, beats steroid alone at 26 weeks

Cingal met primary endpoint in U.S. Phase III study 19-01: superior to TH steroid at 26 weeks (p=0.0406).
August 3, 2022, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Anika Q2 rev $39.7M (+4%); net loss ($2.8M) vs prior profit $6.5M

Q2 revenue $39.7M (+4% YoY); OA Pain Mgmt $25.7M (+6%), Joint Preservation $12.1M (+2%).
June 10, 2022, 7:59 PM ET other materiality 0.25 neutral item 5.02 item 5.07 item 9.01

Anika shareholders approve 250,000-share increase in 2017 incentive plan, reelect directors

Stockholders approved amendment increasing shares under 2017 Omnibus Plan from 4.6M to 4.85M; 10.1M in favor, 2.25M against.
May 5, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Anika Q1 revenue $36.7M (+7% YoY); net loss ($2.9M) vs. income; reaffirms FY22 growth

OA Pain Management revenue $22.7M (+18% YoY); Joint Preservation & Restoration $12.1M (-1%).
March 8, 2022, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Anika reports Q4 2021 revenue $35.8M (+10% YoY); full year $147.8M (+13%); guides FY2022 low-to-mid single digit growth

Q4 2021 revenue $35.8M (+10% YoY); net loss $5.8M ($0.40 diluted) vs $15.7M loss prior year.
November 15, 2021, 6:59 PM ET debt materiality 0.50 neutral item 1.01 item 2.03 item 9.01

Anika Therapeutics enters $75M senior revolving credit facility maturing 2026

Third Amendment to Credit Agreement increases revolving line to $75M, expandable to $150M.
November 4, 2021, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Anika Q3 revenue up 25% to $39.5M, net income $0.6M; cuts FY2021 revenue growth outlook to 9-11% from 11-14%

Revenue $39.5M (+25% YoY); Joint Pain Management up 42% to $26.2M.
November 1, 2021, 7:59 PM ET leadership materiality 0.40 positive item 5.02 item 7.01 item 9.01 ◈ executive_change

Anika Therapeutics appoints Sheryl Conley to Board of Directors; adds orthopedic industry expertise

Appointed Sheryl Conley as independent director effective Oct 28, 2021; board expands from seven to eight members.
August 5, 2021, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Anika Q2 revenue $38.1M (+24% YoY); raises FY revenue growth outlook to 11-14%

Net income $6.5M ($0.45 diluted EPS) vs net loss $7.7M in Q2 2020.